Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074722 | 0.86 | SYK (0.37) | SYKCTRB1KCNA5CTSLCTSB | |
| SCHEMBL10078259 | 0.86 | SYK (0.37) | SYKCTRB1KCNA5CTSLCTSB | |
| SCHEMBL10074471 | 0.86 | SYK (0.37) | SYKCTRB1KCNA5CTSLCTSB | |
| SCHEMBL10078060 | 0.85 | DPP4 (0.36) | — | |
| SCHEMBL6875812 | 0.85 | SCN9A (0.39) | CTSSCTSK | |
| SCHEMBL10074997 | 0.85 | PSMB1 (0.38) | SYKCTRB1CTSLCTSBCTSS | |
| SCHEMBL10074153 | 0.85 | PSMB1 (0.38) | SYKCTRB1CTSLCTSBCTSS | |
| SCHEMBL10054519 | 0.82 | CTRB1 (0.51) | CTRB1KCNA5OPRK1CASP3 | |
| SCHEMBL10074727 | 0.82 | SYK (0.42) | SYKCTSSCTSK | |
| SCHEMBL10078394 | 0.82 | SYK (0.42) | SYKCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | SYK 2686/4885CTRB1 228/4885KCNA5 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.